Therapeutic preferability of gemcitabine for ARID1A-deficient ovarian clear cell carcinoma.
Sign Up to like & getrecommendations! Published in 2019 at "Gynecologic oncology"
DOI: 10.1016/j.ygyno.2019.10.002
Abstract: OBJECTIVE Ovarian clear cell carcinoma (OCCC) is often resistant to conventional, standard chemotherapy using cytotoxic drugs. OCCC harbors a unique genomic feature of frequent (approximately 50%) ARID1A deficiency. The present study was performed to investigate… read more here.
Keywords: gemcitabine; arid1a deficient; deficient occc;